New CEOs Need Digit...
Health Care: Drugs
Halozyme Therapeutics Inc. (HALO: NASDAQ)
$6.32 -0.08 | -1.33%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 6.32 |
| 52 Week High | 9.92 |
| 52 Week Low | 3.86 |
| Avg. Daily Vol. (Mil) | 1.26 |
| Beta (3 year) | 1.45 |
| Share Related Items | |
| Mkt Cap (Mil) | 715.18 |
| Shares Out (Mil) | 113.16 |
| Float (Mil) | 88.81 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 5.00 |
| Current Ratio | 5.60 |
| LT Debt/ Equity | 0.94 |
| Total Debt / Equity | 0.98 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 15.31 |
| Price/Book | 22.57 |
| Price/Cash Flow | -12.70 |
| Per Share Data | |
| Earnings | -0.52 |
| Sales | 0.41 |
| Book Value | 0.28 |
| Cash Flow | -0.50 |
| Business Summary | |
|---|---|
| Halozyme Therapeutics, Inc. is a biopharmaceutical company engaged in develops and commercializes innovative products that advance patient care. | |
| General Information | |
| 11388 Sorrento Valley Road
Suite 17 San Diego, CA 92121 |
|
| www.halozyme.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 152 | |
| CEO: Dr. Gregory I. Frost,PhD | |
| Short Interest | |
| Current Month (Mil) | 8.85 |
| Previous Month (Mil) | 10.07 |
| Short Interest Ratio (Days) | 5.90 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -49.40 |
| Return on Investments | -93.00 |
| Profitability | |
| Gross Margin | 99.00 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with HALO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- UserWatch
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks With Big Insider Buy...
- Contributor3 Stocks to Buy for Less Th...
- UserGFNN Stockdiagnostics 6
- ContributorStocks With Big Insider Buy...
- ContributorStocks At New 52-Week Highs...
Latest HALO Headlines from TheStreet
- 7 Stocks Under $10 Moving Higher 11.15.12 | 03:11 pm
- 5 Stocks With Big Insider Buying 08.29.12 | 11:08 am
- Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript 08.06.12 | 07:08 pm
- 5 Biotech Stocks Under $10 Set to Soar 07.19.12 | 11:07 am
- 5 Stocks Insiders Love Right Now 05.23.12 | 10:05 am
- Insiders Trading HALO, ULTA, HES, NVR 05.18.12 | 10:05 am
- Get These 3 Stocks for Less Than What Insiders Paid 04.30.12 | 01:04 pm
- Mattel, Endocyte, Ivanhoe Are Market Movers 04.16.12 | 05:04 pm
- Halozyme Stock Gaps Down On Today's Open (HALO) 04.16.12 | 10:04 am
- Halozyme Stock Falls On Unusually High Volume (HALO) 04.10.12 | 02:04 pm
Press Releases for HALO
- Halozyme's Phase 1b Clinical Trial Of PEGPH20 With Gemcitabine Indicates Positive Activity Against Pancreatic Cancer - PR Newswire 06.03.13 | 07:06 am
- Halozyme Therapeutics Names David A. Ramsay Chief Financial Officer - PR Newswire 05.23.13 | 08:05 am
- Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society Of Clinical Oncology Annual Meeting - PR Newswire 05.15.13 | 06:05 pm
- Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference - PR Newswire 05.07.13 | 04:05 pm
- Halozyme To Host First Quarter 2013 Financial Results Conference Call - PR Newswire 05.01.13 | 04:05 pm
- Halozyme Initiates Randomized Phase 2 Trial Of PEGPH20 In Pancreatic Cancer - PR Newswire 04.23.13 | 08:04 am
- Halozyme Therapeutics Names Matt Posard To Board Of Directors - PR Newswire 03.28.13 | 04:03 pm
- Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union - PR Newswire 03.22.13 | 08:03 am
- Halozyme Therapeutics To Present At The Barclays 2013 Global Healthcare Conference - PR Newswire 03.05.13 | 04:03 pm
- Halozyme To Host Fourth Quarter And 2012 Year-End Financial Results Conference Call - PR Newswire 02.19.13 | 04:02 pm
Partner Headlines for HALO
- Moves in Smaller Health Care Stocks (ANAC, HALO, PBYI, QCOR) - Benzinga 03.23.13 | 11:03 am
- Market Wrap for Friday, March 22: Stocks Rise on Hopes of Bailout Deal for Cyprus - Benzinga 03.22.13 | 04:03 pm
- Pertaining to Relief for ViroPharma - Analyst Blog - NASDAQ 09.25.12 | 07:09 pm
- ViroPharma Misses Zacks Estimates - Analyst Blog - Zacks 08.10.12 | 09:08 am
- VPHM Manufacturing Process Approved - Analyst Blog - Zacks 08.07.12 | 07:08 pm
- Bad News for ViroPharma - Analyst Blog - Zacks 08.03.12 | 06:08 pm
- After Hours Most Active for Aug 1, 2012 : SAN, GMCR, NOK, FSLR, BBVA, SBUX, BAC, JNJ, LEN, HALO, QQQ, SPLS - NASDAQ 08.01.12 | 08:08 pm
- Rituxan And Its Biosimilar Competitors - Seeking Alpha 07.30.12 | 09:07 am
- Healthcare Biz Recap: GlaxoSmithKline BUYS Drugs, Sanofi Gains Traction - Wall St. Cheat Sheet 06.12.12 | 06:06 am
- Morning Market Losers - Benzinga 04.16.12 | 09:04 am
